Atomoxetine Does Not Cause Cancer
Based on FDA-approved drug labeling and comprehensive preclinical toxicology studies, atomoxetine was not carcinogenic in 2-year animal studies and is not considered to cause cancer in humans. 1
Evidence from Preclinical Carcinogenicity Studies
The FDA label for atomoxetine clearly states that atomoxetine HCl was not carcinogenic in rats and mice when given in the diet for 2 years at doses up to 47 mg/kg/day in rats and 458 mg/kg/day in mice 1. These doses represent:
- 8 times the maximum human dose in children (5 times in adults) for rats on a mg/m² basis
- 39 times the maximum human dose in children (26 times in adults) for mice on a mg/m² basis
The plasma exposure levels (AUC) in these animal studies were 1.8 times higher than human therapeutic levels in extensive metabolizers, providing substantial safety margins 1.
Genotoxicity Testing Results
Atomoxetine was negative in a comprehensive battery of genotoxicity studies including 1:
- Ames Test (reverse point mutation assay)
- In vitro mouse lymphoma assay
- Chromosomal aberration test in Chinese hamster ovary cells
- Unscheduled DNA synthesis test in rat hepatocytes
- In vivo micronucleus test in mice
Important caveat: There was a slight increase in diplochromosomes in Chinese hamster ovary cells, suggesting endoreduplication (a numerical aberration), but this finding did not translate to carcinogenic potential in the 2-year animal studies 1.
Addressing In Silico Predictions
One recent in silico study (2024) predicted potential carcinogenicity risk using computational modeling 2. However, this represents only theoretical computer-based predictions, not actual experimental or clinical evidence. These computational predictions must be interpreted with extreme caution because:
- They contradict the actual 2-year carcinogenicity studies mandated by the FDA
- In silico tools frequently generate false-positive predictions
- Real-world animal and human data take precedence over computational predictions
Clinical Monitoring Recommendations
While atomoxetine does not cause cancer, the FDA label does identify other important safety concerns that require monitoring 3:
- Suicidal ideation in children and adolescents (boxed warning)
- Cardiovascular effects (blood pressure and heart rate monitoring)
- Hepatotoxicity (rare but serious)
- Growth effects in children
The documented adverse effects of atomoxetine are nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence—not cancer 3.
Bottom Line
Atomoxetine has undergone rigorous FDA-mandated carcinogenicity testing and showed no evidence of cancer-causing potential. The drug has been approved and used clinically since 2002 without evidence of increased cancer risk in the post-marketing surveillance period. Concerns should focus on the actual documented risks (suicidality, cardiovascular effects, hepatotoxicity) rather than theoretical carcinogenicity that has been definitively ruled out in animal studies.